Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of efruxifermin in noncirrhotic MASH/NASH with liver fibrosis
MOH_2024-01-23_013194Phase 3Recruiting
- Sponsor
- Akero Therapeutics
- Start
- Dec 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of efruxifermin in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (3 arms), sponsored by Akero Therapeutics. Primary endpoint: Primary histologic efficacy assessment. Started Dec 2023; status: recruiting.
02
Drugs
efruxifermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on MOH_2024-01-23_013194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-23_013194.